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Summary
Background Children aged ≥ 6 to < 12 years with severe atopic dermatitis (AD) have
limited treatment options. In a 16-week, randomized, placebo-controlled, phase III
trial in children, dupilumab, a monoclonal antibody inhibiting interleukin (IL)-4/
IL-13 signalling, significantly improved signs and symptoms with acceptable safety;
longer-term safety and efficacy data are lacking.
Objectives To report the pharmacokinetic profile and long-term safety and efficacy
of dupilumab in children (aged ≥ 6 to < 12 years) with severe AD.
Methods Children (aged ≥ 6 to < 12 years) with severe AD were enrolled in a global,
multicentre, phase IIa, open-label, ascending-dose, sequential cohort study and sub-
sequent open-label extension (OLE) study. Patients received single-dose dupilumab
2 or 4 mg kg1 followed by 8-week pharmacokinetic sampling, then 2 or 4 mg kg1
weekly for 4 weeks (phase IIa), followed by the same weekly regimen (OLE). Pri-
mary endpoints were dupilumab concentration–time profile and treatment-emer-
gent adverse events (TEAEs); secondary assessments included Eczema Area and
Severity Index (EASI) and Peak Pruritus Numeric Rating Scale (PP-NRS) score.
Results Of 38 children enrolled, 37 completed phase IIa and 33 continued to the
OLE. Nonlinear, target-mediated pharmacokinetics characterized dupilumab con-
centrations (week 24–48 mean serum concentrations: 2 mg kg1, 61–77 mg
L1; 4 mg kg1, 143–181 mg L1). TEAEs were mostly mild to moderate and
transient; none led to treatment discontinuation. The most commonly reported
TEAEs were nasopharyngitis (2 mg kg1, 47%; 4 mg kg1, 56%) and AD exacer-
bation (29% and 13%, respectively). Single-dose dupilumab rapidly improved
AD with further improvements through week 52. Mean EASI and PP-NRS
improved by 37%/33% and 17%/20% at week 2 (phase IIa) and 92%/
84% and 70%/58% at week 52 (OLE), respectively.
Conclusions These safety and efficacy results support the use of dupilumab as a
continuous long-term treatment for children aged ≥ 6 to < 12 years with severe
AD.
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What is already known about this topic?
• Severe atopic dermatitis (AD) has a marked negative impact on patient quality of
life and can cause financial burden owing to a lack of effective treatments.
• Dupilumab significantly improved signs and symptoms of AD with an acceptable
safety profile in a 16-week randomized, double-blind, placebo-controlled phase III
study in children aged ≥ 6 to < 12 years with severe AD.
What does this study add?
• This study extends information on the safety, efficacy and pharmacokinetic profile
of dupilumab treatment for up to 52 weeks in children aged ≥ 6 to < 12 years
with severe AD.
• The results support the use of dupilumab as a continuous long-term treatment for
children aged ≥ 6 to < 12 years with severe AD.
Atopic dermatitis (AD) is the most common inflammatory
skin disease in children.1 A recent analysis in children aged ≥
6 to < 12 years showed a prevalence of up to 20%, of which
severe AD accounted for up to 8%.2 The disease has a marked
negative impact on quality of life (QoL), including sleep
deprivation, irritability, and stress and impact on family mem-
bers,3 and is associated with substantial financial burden.4,5
Therapies that ameliorate severe disease with a favourable ben-
efit–risk profile are limited in children with AD.6–8 Systemic
corticosteroids are strongly discouraged in children;9 other
systemic agents are used off-label and provide an unacceptable
long-term benefit–risk profile for paediatric patients whose AD
is inadequately controlled by topical therapies.10 There are
limited data from controlled studies to support the use of
these agents in children.6
Dupilumab, a fully human VelocImmune-derived mono-
clonal antibody,11,12 blocks the shared receptor component
for interleukin (IL)-4 and IL-13, thus inhibiting signalling of
both IL-4 and IL-13. In a 16-week, randomized, double-blind,
placebo-controlled phase III study of dupilumab in children
aged ≥ 6 to < 12 years with severe AD, dupilumab signifi-
cantly improved signs and symptoms with an acceptable safety
profile.13 However, AD is a chronic disease that requires con-
tinuous long-term treatment; therefore, long-term efficacy and
safety data are important to support dupilumab use in this age
group.
We previously reported the short- and long-term (up to 52
weeks) clinical safety, efficacy and pharmacokinetic (PK) pro-
file of dupilumab in adolescents (aged ≥ 12 to < 18 years)
with moderate-to-severe AD in an open-label phase IIa study
(NCT02407756) and an ongoing phase III open-label exten-
sion (OLE) study (NCT02612454; LIBERTY AD PED-OLE).14
Here we present an analysis of the safety, efficacy and PK pro-
file of dupilumab in children aged ≥ 6 to < 12 years included
in these studies.
Materials and methods
Study design and oversight
The study designs for both studies have been previously
reported.14 R668-AD-1412 (NCT02407756), a phase IIa, mul-
ticentre, open-label, ascending-dose, two-part, sequential
cohort study, investigated the PK profile, safety, and efficacy
of dupilumab (Figure 1a, b). In part A, patients received sin-
gle-dose subcutaneous dupilumab (2 or 4 mg kg1) with 8
weeks of follow-up; in part B, patients received four weekly
(qw) doses of subcutaneous dupilumab (2 or 4 mg kg1)
Figure 1 Phase IIa study. (a) Design per original protocol. (b) Study flow diagram of phase IIa study. (c) Study flow diagram of phase III open-
label extension (OLE) study. D, day; PK, pharmacokinetic; W, week. Only data from the subset of patients aged ≥ 6 to < 12 years are reported in
this article. aPart A, single dose followed by an 8-week follow-up period with semidense sampling for systemic drug concentration. bPart B, four
weekly doses followed by an 8-week safety follow-up period. The analysis presented here focuses on patients aged ≥ 6 to < 12 years who
participated in the previous phase IIa study before the data cutoff date of 22 July 2019. Data are presented up to week 52. cFor patients who
completed part A per schedule, day-1 visit of part B was the same visit as week-8 visit of part A. For patients who did not complete part A per
schedule (e.g. patients who received systemic corticosteroid or systemic nonsteroidal immunosuppressive drugs as rescue within 2 weeks of
scheduled start of repeat dose and required 2 weeks of washout of the rescue medication), week-8 visit of part A and day-1 visit of part B were
two independent visits; these patients were to complete the week-8 visit of part A and start visits for part B independent of part A. dOn visits in
which study drug administration was planned, patients had the option to come to the clinic to have the study drug administered by site staff.
eIn-clinic visits occurred every 3 months.
© 2020 The Authors. British Journal of Dermatology
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with an 8-week follow-up. A single 4-mg kg1 dose in paedi-
atric patients was expected to provide similar exposure as a
single 300-mg dose in adults. The 2-mg kg1 dose was cho-
sen as the initial starting dose to evaluate the safety of dupilu-
mab before progressing to the 4-mg kg1 dose. The main
inclusion criteria for children were age ≥ 6 to < 12 years,
documented recent history (≤ 6 months before the screening
visit) of inadequate response to topical AD medication(s),
body surface area involvement ≥ 10% with AD lesions, and an
Investigator’s Global Assessment (IGA) score of 4 at baseline.
Other inclusion criteria were identical to those previously
reported in adolescents.14 The study was conducted at multi-
ple centres in Europe (Czech Republic, Hungary, Germany,
Poland, UK) and Canada (Table S1; see Supporting Informa-
tion).
R668-AD-1434 (LIBERTY AD PED-OLE; NCT02612454) is
an ongoing, long-term, OLE phase III study enrolling paedi-
atric patients who participated in previous dupilumab AD
trials, including the phase IIa study reported here and a
phase III study in children aged ≥ 6 to < 12 years (LIB-
ERTY AD PEDS; R668-AD-1652) (Figure 1c) (long-term
safety and efficacy data were not available from the phase
III study at the time of publication; the phase III study data
will be reported in a future manuscript).13 The aim of the
OLE is to assess the long-term safety and efficacy of dupilu-
mab.
Children aged ≥ 6 to < 12 years were included if they had
participated in a previous dupilumab study and adequately
completed the visits and assessments required per protocol in
the previous study. Patients were excluded if they developed a
serious adverse event (SAE) or an adverse event (AE) deemed
related to dupilumab that presented an unreasonable risk for
the patient during the previous study. Full inclusion and
exclusion criteria have been previously reported.14 In the OLE
study, patients continued to receive their assigned treatment
regimen as in the phase IIa study (2 or 4 mg kg1 adminis-
tered qw).
Low- and mid-potency topical corticosteroids (TCS),
topical calcineurin inhibitors, or both were allowed at the
discretion of the investigator in either study. The use of
systemic treatments for AD (systemic immunosuppressants
and corticosteroids) was prohibited. If required, rescue
treatment could be considered, initially with higher-po-
tency TCS and then escalated to systemic treatment (corti-
costeroids or noncorticosteroid immunosuppressants;
study treatment discontinuation was required during res-
cue treatment use).14
The studies were conducted in accordance with the provi-
sions of the Declaration of Helsinki, the International Confer-
ence on Harmonization Good Clinical Practice guideline and
applicable regulatory requirements. The protocol was reviewed
and approved by institutional review boards/ethics commit-
tees at all study sites. An independent data monitoring com-
mittee monitored patient safety. For all patients, written
informed consent was obtained from a parent or legal guar-
dian and assent was obtained from the patient.
The phase IIa and OLE data presented here only include
children aged ≥ 6 to < 12 years who participated in both
studies. The OLE data is provided for 52 weeks of treatment.
Outcomes
The full list of prespecified endpoints has been previously
reported.14 The primary endpoint of the phase IIa study was
concentration of functional dupilumab in serum over time
and other PK parameters. The main secondary outcomes
included incidence of treatment-emergent AEs (TEAEs) and
percentage changes from baseline in Eczema Area and Severity
Index (EASI), SCORing Atopic Dermatitis (SCORAD) and Peak
Pruritus Numerical Rating Scale (NRS). The phase III OLE pri-
mary endpoints were incidence and rate [events per patient-
year (PY)] of TEAEs. The main secondary endpoints included
incidence and rate (events per PY) of serious TEAEs and TEAEs
of special interest, the proportion of patients with an IGA
score of 0 or 1, the proportion of patients with ≥ 75% reduc-
tion in EASI (EASI 75) from baseline of the parent study, the
percentage change from baseline of the parent study in EASI
score and SCORAD score, and the change from OLE baseline
in Patient-Oriented Eczema Measure (POEM) and Children’s
Dermatology Life Quality Index (CDLQI).
Pharmacokinetics
PK samples were collected in a semidense manner in part A of
the phase IIa study and at sparse timepoints in part B of the
phase IIa and the OLE studies. To limit blood draws in this
paediatric population, patients were randomized to a sampling
schedule that included a subset of potential timepoints
(Appendix S1; see Supporting Information). The mean con-
centration–time profiles were generated from pooling of all
collected samples and used to determine the time to maxi-
mum mean concentration (tmax) and area under the concen-
tration–time curve from time zero to the time of last
measurable concentration in part A (AUClast). Maximum dupi-
lumab concentration in serum (cmax) were calculated for
patients with PK samples collected at the tmax timepoint. In
the OLE, steady-state Ctrough samples were evaluated over
weeks 24–48. Serum samples for dupilumab were analysed
using a validated enzyme-linked immunosorbent assay, with a
lower limit of quantitation set at 0078 mg L1. The PK analy-
sis set included patients with at least one nonmissing func-
tional dupilumab result following the first dose of the study
drug.
Statistical analysis
No formal sample size or power calculations were performed.
PK, safety and efficacy variables were summarized descrip-
tively; no inferential statistical tests were prespecified in the
statistical analysis plan to allow comparison between treatment
arms. Any differences observed in the descriptive summary of
the PK, safety and efficacy variables were based on numerical
© 2020 The Authors. British Journal of Dermatology
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comparisons. Exposure-adjusted analyses were calculated as
described in Appendix S2 (see Supporting Information). The
safety and efficacy analysis sets for all statistical analyses for
both studies included all patients who received any study
drug. Data after rescue treatment use during part B of the
phase IIa study were set to missing. For continuous endpoints,
missing values during the 4-week repeat-dose treatment per-
iod of part B up to the end-of-treatment visit were imputed
by the last observation carried forward method. After the end
of treatment in part B, no missing data were imputed. For cat-
egorical variables, patients with missing values were consid-
ered as nonresponders. Patients withdrawn from the study
were counted as nonresponders after withdrawal. Patients who
received rescue treatment during part B were considered non-
responders from the time of rescue use. For the phase III OLE
study, an all-observed method was employed, regardless of
rescue treatment use or whether data were collected after
withdrawal from treatment (no missing values imputed). Sta-
tistical Analysis Software version 92 (SAS Institute, Inc., Cary,
NC, USA) was used for all analyses.
Results
Patients
A total of 38 children (aged ≥ 6 to < 12 years) were enrolled
(Figure S1; see Supporting Information). One patient (3%) in
the 4 mg kg1 dose group was withdrawn from the study
during part A (withdrawal of consent owing to fear of study
injections). Overall, 37 children (97%) completed parts A and
Table 1 Baseline demographics and disease characteristics
Phase IIa study (N = 37) Phase III OLE study (N = 33)
2 mg kg1 (n = 18) 4 mg kg1 (n = 19) 2 mg kg1 (n = 17) 4 mg kg1 (n = 16)
Mean age  SD (range) (years) 8  2 (6–11) 8  2 (6–11) 9  2 (6–11) 8  2 (6–11)
Race, n (%)
White 17 (94) 18 (95) 16 (94) 15 (94)
Black or African American 0 1 (5) 0 1 (6)
Other 1 (6) 0 1 (6) 0
Male sex, n (%) 9 (50) 11 (58) 8 (47) 9 (56)
Mean  SD weight (kg) 308  87 296  98 309  90 293  86
Mean  SD BMI (kg m2) 175  28 168  20 169  30 170  22
Mean  SD duration of AD (years) 7  2 7  2 7  3 8  2
Mean  SD EASI score (scale 0–72) 33  16 39  19 21  18 32  20
IGA score, n (%) (scale 0–4)
0 or 1 N/A N/A 1 (6) 0
2 N/A N/A 3 (18) 1 (6)
3 1 (6)a 0 9 (53) 7 (44)
4 17 (94) 19 (100) 4 (24) 8 (50)
Mean  SD Peak Pruritus NRS (scale 0–10) 6  2 7  2 6  3 6  2
Mean  SD BSA affected by AD (%) 59  22 62  30 37  27 50  31
Mean  SD SCORAD (scale 0–103) 66  13 73  13 52  17 67  18
Mean  SD POEM (scale 0–28) N/A N/A 17  8 20  5
Mean  SD CDLQI (scale 0–30) N/A N/A 12  8 12  4
Any previous nonsteroidal systemic
immunosuppressants, n (%)
3 (17) 7 (37) N/A N/A
Azathioprine 0 2 (11) N/A N/A
Ciclosporin A 3 (17) 5 (26) N/A N/A
No response to previous nonsteroidal
systemic immunosuppressants
1 (6) 5 (26) N/A N/A
Patients with current history of atopic allergic
conditions excluding AD, n (%)
14 (78) 17 (89) N/A N/A
Allergic rhinitis 9 (50) 10 (53) N/A N/A
Food allergy 10 (56) 14 (74) N/A N/A
Asthma 7 (39) 9 (47) N/A N/A
Allergic conjunctivitis 3 (17) 5 (26) N/A N/A
Chronic rhinosinusitis 0 1 (5) N/A N/A
Urticaria 1 (6) 0 N/A N/A
Other allergies 12 (67) 12 (63) N/A N/A
AD, atopic dermatitis; BMI, body mass index; BSA, body surface area; CDLQI, Children’s Dermatology Life Quality Index; EASI, Eczema Area
and Severity Index; IGA, Investigator’s Global Assessment; N/A, not applicable; NRS, Numerical Rating Scale; OLE, open-label extension;
POEM, Patient-Oriented Eczema Measure; SCORAD, SCORing Atopic Dermatitis. aOne patient from this age group enrolled in the study had a
baseline disease severity of IGA = 3 but was still included in the analyses sets.
© 2020 The Authors. British Journal of Dermatology
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B. All 37 patients continued in the paediatric OLE; four
patients turned 12 years of age at the time of enrolment and
are not included in this analysis. The mean durations between
the last dose in the phase IIa study and the first dose in the
OLE were 118 days and 97 days for the 2-mg kg1 and 4-mg
kg1 dose groups, respectively.
Baseline demographics and disease characteristics are shown
in Table 1. The mean ( SD) age was 8 years ( 2) and the
mean duration of AD was 7 years ( 2) in both dose groups.
Disease characteristics at phase IIa study baseline were consis-
tent with severe AD (Table 1). Mean ( SD) EASI scores were
33 ( 16) and 39 ( 19), Peak Pruritus NRS scores were 6
( 2) and 7 ( 2) and percentages of body surface area
affected were 59% ( 22) and 62% ( 30) in the 2-mg kg1
and 4-mg kg1 groups, respectively. Baseline disease severity
was numerically higher in the 4-mg kg1 group compared
with the 2-mg kg1 group in both the phase IIa and OLE
studies (Table 1). Three patients (17%) in the 2-mg kg1
group and seven patients (37%) in the 4-mg kg1 group
received nonsteroidal immunosuppressants prior to baseline of
the phase IIa study; one patient (6%) and five patients (26%)
did not respond to this treatment, respectively. Most patients
(78%, 2 mg kg1; 89%, 4 mg kg1) had other concomitant
atopic/allergic diseases, including asthma, allergic rhinitis and
food allergy (Table 1).
Dupilumab pharmacokinetic profile
Following a single subcutaneous dose of dupilumab on day 1
of the phase IIa study, AUClast calculated from the mean
concentration–time profile in serum was 160 day 9 mg L1
and 330 day 9 mg L1 for the 2 mg kg1 and 4 mg kg1
groups, respectively. In the 2-mg kg1 group, tmax was
observed at 2 days after dosing with a cmax ( SD) of 143
mg L1 ( 59). In the 4-mg kg1 group, tmax was observed
4 days after dosing with a cmax ( SD) of 324 mg L
1
( 70) (Figure 2a, Figure S2a; see Supporting Information).
In the OLE, steady-state dupilumab trough mean ( SD) con-
centrations at weeks 24–48 ranged from 613 ( 350) to
768 mg L1 ( 358) in the 2-mg kg1 qw group and 143
( 403) to 181 mg L1 ( 659) in the 4-mg kg1 qw
group (Figure 2a, Figure S2a; see Supporting Information).
Safety assessment
The majority of reported TEAEs in the phase IIa were of mild
or moderate severity (14% of patients reported a severe
TEAE). The overall incidence of serious TEAEs was low, with
two patients (11%) experiencing a serious TEAE, both of
whom were in the 4-mg kg1 dose group in part A of the
study (Table 2). Serious TEAEs included bacterial arthritis,
infected dermatitis and AD exacerbation, which were deemed
not related to treatment (Appendix S3; see Supporting Infor-
mation). None of the events led to permanent treatment dis-
continuation (Table 2).
The most frequent TEAEs were nasopharyngitis and AD
exacerbation (Table 2). The proportion of patients with TEAEs
was numerically higher in the 4-mg kg1 dose cohort than in
the 2-mg kg1 dose cohort (Table 2), which was driven by
higher incidence of skin infections (high-level term), cough
(a) (b)
Figure 2 (a) Mean log-scaled concentrations of dupilumab in serum vs. nominal time: concentration–time profile of the phase IIa study. (b)
Mean log-scaled concentrations of dupilumab in serum vs. nominal time: concentration–time profile of the phase III open-label extension (OLE)
study.Horizontal arrows show timepoints of dupilumab administration. For both panels, concentrations below the limit of quantitation were set as
LLOQ/2. LLOQ, lower limit of quantitation.
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(preferred term) and infected dermatitis (preferred term). Skin
infections and AD exacerbation occurred mostly in patients
not on dupilumab treatment at the time of TEAE onset (fol-
low-up periods of parts A or B). Injection-site reactions were
mild, occurring in the 4-mg kg1 dose group alone (Table 2).
Three patients reported conjunctivitis events, all in the 4-mg
kg1 group (in both parts A and B), none of which were sev-
ere, serious or led to treatment discontinuation; conjunctivitis
resolved in two patients. One patient per dose group reported
nonherpetic viral infections in part A.
In the OLE, nearly all children reported at least one TEAE
(Table 2). However, serious TEAEs were rare, with two
patients (12%) and three patients (19%) experiencing at least
one serious TEAE in the 2-mg kg1 and 4-mg kg1 dose
groups, respectively; none were related to treatment or led to
discontinuation of study drug. In the OLE, the most frequent
TEAEs were nasopharyngitis and AD exacerbation (Table 2).
The proportions of patients with TEAEs, including skin infec-
tions, were comparable in the 4-mg kg1 and 2-mg kg1
groups. However, there was a trend towards numerically
Table 2 Safety assessment
Phase IIa study (N = 37) Phase III OLE study (N = 33)
2 mg kg1 (n = 18) 4 mg kg1 (n = 19)
2 mg kg1
(n = 17)
4 mg kg1
(n = 16)
2 mg kg1
(n = 17)
4 mg kg1
(n = 16)
Part A Part B Part A Part B
Number of TEAEs n n nE per 100 PYs
Total TEAEs 18 23 47 47 136 139 353 458
Total serious TEAEsa 0 0 3 0 2 5 5 16
Total TEAEs related to
treatment
0 1 4 4 14 2 36 7
Total serious TEAEs related to
treatment
0 0 0 0 0 0 0 0
Total TEAEs resulting in
permanent
study drug discontinuation
0 0 0 0 0 0 0 0
Patients with TEAEs n (%) n (%) nP per 100 PYs
Any TEAE 9 (50) 10 (56) 16 (84) 17 (89) 16 (94) 16 (100) 266 471
Any serious TEAE 0 0 2 (11) 0 2 (12) 3 (19) 6 11
Any TEAE related to
treatment
0 1 (6) 3 (16) 3 (16) 4 (24) 2 (13) 13 7
Any TEAE leading to
treatment discontinuation
0 0 0 0 0 0 0 0
Patients with TEAE resulting
in death
0 0 0 0 0 0 0 0
Any infection (SOC) 6 (33) 8 (44) 10 (53) 12 (63) 12 (71) 15 (94) 98 209
Skin infection (HLT) 1 (6) 1 (6) 7 (37) 5 (26) 5 (29) 6 (38) 17 25
Nonherpetic skin infections
(adjudicated)
1 (6) 1 (6) 6 (32) 5 (26) 4 (24) 3 (19) 12 11
Herpes viral infections
(HLT)
1 (6) 0 1 (5) 0 2 (12) 4 (25) 6 15
Injection-site reactions (HLT) 0 0 1 (5) 1 (5) 2 (12) 1 (6) 5 3
Conjunctivitisb 0 0 1 (5) 2 (11) 2 (12) 5 (31) 5 21
Most common TEAEsc
Nasopharyngitis 3 (17) 4 (22) 6 (32) 4 (21) 8 (47) 9 (56) 35 37
Dermatitis atopic 4 (22) 4 (22) 5 (26) 3 (16) 5 (29) 2 (13) 16 7
Cough 0 1 (6) 5 (26) 3 (16) 2 (12) 5 (31) 6 20
Dermatitis infected 1 (6) 0 3 (16) 2 (11) 2 (12) 0 5 0
Headache 0 1 (6) 2 (11) 1 (5) 4 (24) 2 (13) 13 7
Upper respiratory tract
infection
0 1 (6) 0 1 (5) 2 (12) 4 (25) 6 16
Herpes simplex 0 0 0 0 0 4 (25) 0 15
HLT, high-level term; MedDRA, Medical Dictionary for Regulatory Activities; nE, number of events; nP, number of patients; OLE, open-label
extension; PT, preferred term; PYs, patient-years; SOC, system organ class; TEAE, treatment-emergent adverse event. aSerious TEAEs reported
in the OLE included lymphadenopathy, anaphylactic reaction, pneumonia, allergy test, arthralgia, complex regional pain syndrome and postu-
ral dizziness. bIncludes PTs, conjunctivitis allergic, conjunctivitis bacterial, conjunctivitis, conjunctivitis viral and atopic keratoconjunctivitis.
cIncludes all MedDRA PTs reported in ≥ 15% or ≥ 20% of patients in any treatment group of the phase IIa study or phase III OLE, respec-
tively.
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Table 3 Efficacy assessment
Dupilumab 2 mg kg1 Dupilumab 4 mg kg1
Phase IIa study (n = 18) Phase III OLE (n = 17) Phase IIa study (n = 19) Phase III OLE (n = 16)
Week 2 Week 12 Week 0a Week 16 Week 52 Week 2 Week 12 Week 0a Week 16 Week 52
Mean  SD EASI
(n)
23  18 (18) 9  13 (16) 21  18 (17) 9  14 (17) 2  3 (17) 26  16 (18) 16  15
(19)
32  20 (16) 7  8 (15) 5  5 (16)
Mean  SD
percentage
change in EASI
from baseline of
phase IIa study
(N1)
37  34
(18)
76  25 (16) 37  37 (17) 73  42 (170) 92  14 (17) 33  28 (18) 63  25
(19)
20  32
(16)
84  14
(15)
84  17
(16)
Patients achieving
EASI 50 from
baseline of phase
IIa study, n/N
(%)
7/18 (39) 14/18 (78) 7/17 (41) 16/17 (94) 16/17 (94) 5/19 (26) 11/19 (58) 3/16 (19) 14/15 (93) 15/16 (94)
Patients achieving
EASI 75 from
baseline of phase
IIa study, n/N
(%)
3/18 (17) 10/18 (56) 4/17 (24) 10/17 (59) 16/17 (94) 2/19 (11) 9/19 (47) 1/16 (6) 11/15 (73) 12/16 (75)
Patients with EASI
90 from baseline
of phase IIa
study, n/N (%)
1/18 (6) 6/18 (33) 0/17 (0) 7/17 (41) 12/17 (71) 0/19 (0) 5/19 (26) 0/16 (0) 5/15 (33) 7/16 (44)
Patients achieving
IGA score 0 or
1, n/N (%)
1/18 (6) 3/18 (17) 1/17 (6) 6/17 (35) 13/17 (76) 0/19 (0) 4/19 (21) 0/16 (0) 6/15 (40) 4/16 (25)
Mean  SD Peak
Pruritus NRS
(N1)
5  3 (17) 3  2 (16) 6  3 (17) 3  2 (17) 2  2 (17) 5  3 (18) 4  2 (19) 6  2 (16) 3  2 (16) 3  2 (16)
(continued)
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Table 3 (continued)
Dupilumab 2 mg kg1 Dupilumab 4 mg kg1
Phase IIa study (n = 18) Phase III OLE (n = 17) Phase IIa study (n = 19) Phase III OLE (n = 16)
Week 2 Week 12 Week 0a Week 16 Week 52 Week 2 Week 12 Week 0a Week 16 Week 52
Mean  SD
percentage
change in Peak
Pruritus NRS
from baseline of
phase IIa study
(N1)
17  46
(17)
42  35
(16)
9  39 (17) 50  42 (17) 70  32 (17) 20  47 (18) 40  41
(19)
5  68 (16) 51  44
(16)
58  33
(16)
Patients with ≥ 3-
point
improvement in
Peak Pruritus
NRS from
baseline of phase
IIa study, n/N
(%)
4/18 (22) 7/18 (39) 4/17 (24) 11/17 (65) 14/17 (82) 7/19 (37) 10/19 (53) 6/16 (38) 11/16 (69) 11/16 (69)
Patients with ≥ 4-
point
improvement in
Peak Pruritus
NRS from
baseline of phase
IIa study, n/N
(%)
2/18 (11) 5/18 (28) 1/17 (6) 9/17 (53) 11/17 (65) 5/19 (26) 9/19 (47) 3/16 (19) 11/16 (69) 11/16 (69)
Mean  SD
SCORAD (N1)
51  20 (17) 28  15 (16) 52  17 (17) 26  20 (17) 14  11 (17) 52  15 (18) 38  17 (19) 67  18 (16) 29  15 (15) 24  14
(16)
Mean  SD
percentage
change in
SCORAD from
baseline of phase
IIa study (N1)
25  21 (17) 58  23 (16) 22  20 (17) 61  31 (17) 79  16 (17) 28  19
(18)
47  24 (19) 10  23 (16) 62  18 (15) 67  19
(16)
EASI, Eczema Area and Severity Index; EASI 50/75/90, ≥ 50%/75%/90% improvement from baseline in EASI; IGA, Investigator’s Global Assessment; N1, patients with available measurements at the
particular timepoint; NRS, Numerical Rating Scale; OLE, open-label extension; SCORAD, SCORing Atopic Dermatitis. aThe mean durations between the last dose in the phase IIa study and the first dose
in the phase III OLE were 118 and 97 days for the 2-mg kg1and 4-mg kg1 dose groups, respectively.
©
2020
The
A
uthors.
British
Journal
of
D
erm
atology
published
by
John
W
iley
&
Sons
Ltd
on
behalf
of
British
A
ssociation
of
D
erm
atologists
British
Journal
of
D
erm
atology
(2020)
O
p
e
n
-la
b
e
l
d
u
p
ilu
m
a
b
in
ch
ild
re
n
w
ith
se
ve
re
a
to
p
ic
d
e
rm
a
titis,
M
.J.
C
o
rk
e
t
a
l.
9
higher TEAEs in the 4-mg kg1 compared with the 2-mg
kg1 group when exposure-adjusted incidence (number of
patients per 100 PY) was examined (Table 2). Two patients
(12%) and four patients (25%) reported herpes viral infection
(Table 2). Injection-site reactions were mild and occurred in
three patients across both dose groups (Table 2). Seven
patients reported conjunctivitis events; two patients (12%)
and five patients (31%) in the 2-mg kg1 and 4-mg kg1
group, respectively (Table 2). Conjunctivitis was reported as
treatment-related in one patient (6%) in the 4-mg kg1
group. Most patients with conjunctivitis events were treated
with topical eyedrops, including antibacterial and antiallergic
eyedrops (Table S2; see Supporting Information). No events
were severe, serious or led to treatment discontinuation, and
conjunctivitis resolved in all patients. Details of conjunctivitis
cases are provided in Table S2 (see Supporting Information).
The most common treatments administered for skin infections
in the phase IIa and OLE studies were topical antimicrobials.
Details of skin infection cases for which systemic antibiotics
were administered are provided in Table S3 (see Supporting
Information).
Efficacy outcomes
By week 2 of the phase IIa study, EASI decreased with a mean
( SD) percentage change from baseline of 37 ( 34) and
33 ( 28) after a single dose of dupilumab 2 mg kg1 and
4 mg kg1, respectively; improvements in EASI were main-
tained up to week 52 in the OLE [92 ( 14) and 84
( 17) in 2-mg kg1 and 4-mg kg1 groups, respectively
(Table 3, Figure 3a, Figure S3a; see Supporting Information)].
The proportions of patients achieving EASI 75 or IGA 0/1 at
week 12 in the phase IIa study further increased until week
52 in the OLE. By week 12 of the phase IIa study, 56% and
47% of patients receiving dupilumab 2 mg kg1 and 4 mg
kg1 achieved EASI 75, with proportions increasing to 94%
and 75% at week 52 of the OLE, respectively (Table 3, Fig-
ure 3b). Similarly, by week 12 of the phase IIa study, 17%
and 21% of patients receiving dupilumab 2 mg kg1 and 4
mg kg1 achieved IGA 0/1 with proportions further increas-
ing to 76% and 25% at week 52 of the OLE, respectively
(Table 3, Figure 3c).
Peak Pruritus NRS scores decreased from baseline by a mean
( SD) percentage of 17% ( 46) and 20% ( 47) at
week 2 of the phase IIa study, after a single dose of dupilu-
mab 2 mg kg1 and 4 mg kg1, respectively; improvements
were maintained up to week 52 in the OLE [70% ( 32)
and 58% ( 33), 2 mg kg1 and 4 mg kg1, respectively]
(Table 3, Figure 3d). Further improvements in other pruritus
outcomes (patients with ≥ 3-point or ≥ 4-point reduction
from baseline in Peak Pruritus NRS) were seen until week 52
in the OLE (Table 3, Figure 3e, Figure S3d; see Supporting
Information).
Sustained improvements were also seen in EASI 50, EASI
90, SCORAD and percentage body surface area affected by AD
in the phase IIa and OLE study up to week 52 (Table 3, Fig-
ure 3f,g, Figure S3b, c, e, f; see Supporting Information). AD
symptoms and QoL as assessed by POEM and CDLQI showed
improvement from baseline to week 48 of the OLE (Figure 3h,
Figure S3g; see Supporting Information).
Concomitant medications
Overall, 89% of patients in the 2-mg kg1 dupilumab
group and 95% of patients in the 4-mg kg1 dupilumab
group of the phase IIa study used topical treatment as con-
comitant medication (Table S4; see Supporting Information);
the most commonly used topical treatment in both treat-
ment arms was potent TCS (group III). In the OLE, 82% (2
mg kg1) and 94% (4 mg kg1) of children used con-
comitant topical medication, with the majority (65% and
69%) using potent (group III) TCS (Table S4; see Support-
ing Information).
Discussion
Children have a developing and potentially immature immune
system, and the immune mechanisms underlying AD in chil-
dren may differ from those in adults.15,16 Hence, it was
important to assess the safety and efficacy of long-term dupi-
lumab-mediated IL-4 receptor a blockade in dedicated clinical
trials in children with AD aged ≥ 6 to < 12 years and to com-
pare the results with those observed in previous adult and
adolescent studies. In children aged ≥ 6 to < 12 years with
severe AD, dupilumab treatment for up to 52 weeks was well
tolerated with a favourable safety profile consistent with the
known dupilumab safety profile from studies in adolescents
and adults with moderate-to-severe AD.14,17–20 No AEs led to
Figure 3 Efficacy endpoints. (a) Percentage change in EASI from baseline of the phase IIa study to week 52 of the phase III OLE. (b) Proportion
of patients achieving EASI 75 from the baseline of the phase IIa study to week 52 of the phase III OLE. (c) Proportion of patients achieving IGA
scores of 0 or 1 from the baseline of the phase IIa study to week 52 of the phase III OLE. (d) Percentage change in Peak Pruritus NRS from the
baseline of the phase IIa study to week 52 of the phase III OLE. (e) Proportion of patients with ≥ 4-point improvement from baseline in Peak
Pruritus NRS at all in-clinic visits postbaseline of parent study through week 52 of OLE study. (f) Percentage change in SCORAD from baseline of
the phase IIa study to week 52 of the phase III OLE. (g) Change in BSA affected by AD from baseline of the phase IIa study to week 52 of the
phase III OLE study. (h) Change in CDLQI from baseline of the OLE study to week 48.AD, atopic dermatitis; BSA, body surface area; CDLQI,
Children’s Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; EASI 75, ≥ 75% improvement from baseline in EASI; IGA,
Investigator’s Global Assessment; NRS, Numerical Rating Scale; OLE, open-label extension; SCORAD, SCORing Atopic Dermatitis. The mean
durations between the last dose in the phase IIa study and the first dose in the phase III OLE were 118 and 97 days for the 2-mg kg1 and 4-mg
kg1 dose groups, respectively.
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treatment discontinuation, and none of the reported serious
TEAEs were considered related to dupilumab.
Although TEAE incidence was higher in the 4-mg kg1
dose group compared with the 2-mg kg1 dose group in the
phase IIa study, TEAE incidences were comparable in the OLE.
No substantial differences in SAEs or TEAEs leading to treat-
ment discontinuation were observed between the two dose
regimens. Moreover, patients in this sequential cohort study
were not randomized to dose regimens, leading to differences
in OLE baseline disease severity, and the number of patients
in each dose regimen was small; therefore, a rigorous compar-
ison between the dose regimens was not possible.
The serious event of septic arthritis reported in the phase
IIa study was deemed not related to dupilumab. The investiga-
tor noted that the patient’s skin was colonized with staphylo-
cocci and skin breakdown from scratching can enable bacteria
to enter the bloodstream, resulting in invasive infection at
metaphyses and, subsequently, arthritis.21,22
Although a higher incidence of skin infection was noted with
the 4-mg kg1 dose compared with the 2-mg kg1 dose in the
phase IIa study, rates were similar in the OLE. Skin infections
occurred mostly in patients not treated with dupilumab at the
time of TEAE onset (patients were in the follow-up periods of
parts A or B). A very high proportion of patients with AD have
skin colonization with Staphylococcus aureus,23 and patients with AD
are prone to developing skin infections. Phase III trials in adults
and adolescents with AD showed that the incidence of skin infec-
tions was numerically lower in patients treated with dupilumab
compared with placebo.20,24 For comparison with exposure-ad-
justed incidence of skin infections in the OLE study reported here
(17–25 patients per 100 PYs), a 1-year open-label study in ado-
lescents observed skin infections in 18–34 patients per 100 PYs14
and a 3-year open-label study in adults found the incidence to be
five patients per 100 PYs.25
The rates of conjunctivitis in the phase IIa study were small,
an observation also made in a similar analysis of adolescents,14
which could be explained in part by the short study duration
and low number of dupilumab doses. Furthermore, the studies
reported here were conducted before investigators developed a
heightened awareness of conjunctivitis as an AE associated
with dupilumab, which may lead to higher reporting in more
recent studies. The incidences of conjunctivitis in the OLE in
children aged ≥ 6 to < 12 years reported here (five to 21
patients per 100 PYs) were similar to those reported in ado-
lescents (nine to 10 patients per 100 PYs)14 and adults (12
patients per 100 PYs).25
AD signs and symptoms, including pruritus, showed rapid
improvements with single-dose dupilumab in the phase IIa
study. Improvements in clinical scores (EASI, SCORAD) and
Peak Pruritus NRS were observed as early as week 2, with fur-
ther improvement on continued treatment up to week 52 in
the OLE. QoL was also improved with long-term treatment.
Comparison of the two doses showed a numerical trend
towards higher responses with 2 mg kg1 vs. 4 mg kg1 in
the treatment of AD signs and symptoms in both the phase IIa
and OLE studies. However, the number of patients in each
treatment arm was small, precluding any meaningful conclu-
sions. Moreover, the baseline disease severity in the 4-mg
kg1 group was higher than the baseline severity in the 2-mg
kg1 group, which could have led to this difference.
The overall efficacy results were similar to those observed
in the first report of these two studies in adolescents with
moderate-to-severe AD.14 The efficacy and safety from another
randomized placebo-controlled phase III study in children
aged ≥ 6 to < 12 years with severe AD receiving dupilumab
with concomitant TCS in a larger sample size of this patient
population were generally similar to our results.13 To compare
efficacy outcomes reported here with other systemic medica-
tions in children, treatment of patients aged 2–16 years with
ciclosporin at a dose of 5 mg kg1 in a randomized double-
blinded placebo-controlled study led to reduction in disease
severity by 50% at week 12.26 Efficacy was sustained with
continuous treatment through week 52. In an open-label
uncontrolled study in paediatric patients aged 2–16 years,
treatment with ciclosporin 5 mg kg1 led to a 57% reduction
in disease severity at week 6.27
The PK profile in children with severe AD was similar to
that in adults and adolescents with moderate-to-severe AD and
characterized by nonlinear target-mediated kinetics.14,28 Mean
Ctrough values at steady state for the 2-mg kg
1 qw dosing
regimen in children were equivalent to the every 2 weeks
(q2w) dosing regimen approved by the US Food and Drug
Administration in adults (300 mg) and adolescents (200/300
mg, tiered by bodyweight), whereas the steady-state Ctrough
for the 4-mg kg1 qw regimen in children was equivalent to
the 300-mg qw regimen in adults. The observation of numeri-
cally higher efficacy with 2 mg kg1 compared with 4 mg
kg1, which most likely occurred by chance, is not inconsis-
tent with the observation that maximal efficacy, and hence sat-
uration of IL-4 receptor a, occurs at mean steady-state Ctrough
of dupilumab equivalent to that achieved by the 300-mg q2w
regimen in adults (approximately 70 mg L1). Importantly,
the lack of incremental efficacy seen with 4 mg kg1 coupled
with the PK data support the evaluation of the q2w regimen
rather than the qw regimen in the pivotal phase III study in
children aged ≥ 6 to < 12 years.13
Strengths of this analysis include results based on continu-
ous treatment with dupilumab for up to 1 year. Limitations
include the open-label nature of the studies, lack of a com-
parator arm and the small sample size. The 5-year OLE study
is ongoing at the time of this report, and future publications
will report larger cohorts and longer treatment durations.
These safety and efficacy results support the use of dupilu-
mab as continuous long-term treatment for children aged ≥ 6
to < 12 years with severe AD.
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